<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03233412</url>
  </required_header>
  <id_info>
    <org_study_id>BarretosCH-20171</org_study_id>
    <nct_id>NCT03233412</nct_id>
  </id_info>
  <brief_title>Evaluating the Efficacy of Immunomodulatory Topical Treatment of Cervical High-grade Intraepithelial Lesions</brief_title>
  <official_title>Ensaio clínico Randomizado Avaliando a eficácia do Tratamento tópico Imunomodulador de lesões Intraepiteliais Cervicais de Alto Grau</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barretos Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Farmoquimica S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Barretos Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cervical cancer is one of the leading malignancies affecting women, with 266,000 deaths in
      2012, most of them seen in underdeveloped countries. This neoplasm has a pre-invasive state,
      such as cervical intraepithelial neoplasia (CIN), which is caused by HPV (Human
      Papillomavirus) infection. The female organism most often is able to eliminate the virus,
      especially in young patients. However, when the infection becomes persistent, especially for
      subtypes 16 and 18, the risk of CIN developing an increased. Cytological screening programs
      can efficiently and wirelessly do this. As high-grade intraepithelial lesions (CIN 2/3) are
      as demonstrated by worse regression rate, only 13.3% at one year, and higher risk for
      progression to invasive cancer. As CIN 2/3 need treatment, and as more therapies as they are
      excisional, which theoretically are better, however, they may compromise the reproductive
      future of women who are unthreatened, increasing the risk of preterm labor, premature rupture
      of amniotic membranes, low weight Birth and perinatal mortality. This relationship aroused
      interest in seeking alternative therapies. Decrease antiviral activity directed against HPV,
      associated with a higher rate of elimination of the infection. Immediate, an agent that
      stimulates like dendritic cells to producer cytokines and activates epithelial T cells.
      Imiquimode, when used in vulvar neoplasias, has been shown to be effective, presenting
      satisfactory results without treatment of CIN 2/3 of the uterine cervix, requiring a better
      scientific compilation. Based on these data, this study aims to evaluate the efficacy of
      topical immunomodulatory treatment for high-grade cervical intraepithelial lesions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">August 7, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients between 25 and 50 years old with histological diagnosis of high-grade intraepithelial lesion, obtained through satisfactory colposcopy and without previous treatment, who will be selected in the preventive clinic of the Hospital de Cancer de Barretos-SP (HCB ). Eligible patients will be identified at the return visit, when they will come to the hospital to check the result of the examination. In this study the patients will be randomized into two groups: Group 1: Control, where standard treatment will be offered, which is the conization of the uterine cervix with loop electrosurgical excision procedure(LEEP); Group 2: experimental group, which will receive topical treatment in the uterine cervix with immunomodulator (Imiquimod), for a period of 12 weeks, with weekly applications (1x / week). 30 to 60 days after immunomodulatory treatment the patient will be submitted to standard treatment with cervical conization with LEEP.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of immunomodulatory treatment with Imiquimod in high grade intraepithelial lesions of the cervix compared to standard electrosurgical excision procedure (LEEP) treatment.</measure>
    <time_frame>30 months</time_frame>
    <description>We will evaluate the efficacy of the Imiquimod treatment applied by the physician after histological examination of the uterine cervix obtained by electrosurgical excision procedure (LEEP) and compare the rate of relapse / reoperation with the control patient only submitted to the standard treatment with LEEP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local and systemic adverse events</measure>
    <time_frame>30 months</time_frame>
    <description>To assess the local and systemic adverse effects of topical immunomodulatory treatment through anamnesis and physical examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare CIN 2 and CIN 3 for the difference in response to immunomodulatory treatment</measure>
    <time_frame>30 months</time_frame>
    <description>It will be evaluated separately from the results of the treatment response with Imiquimod in CIN 2 and CIN 3 lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definition of the difference in cost from actual standard treatment compared to Imiquimod</measure>
    <time_frame>30 months</time_frame>
    <description>The value in Brazilian reais of treatment with Imiquimod will be defined as compared to the amount spent for the standard treatment with LEEP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of recurrence of high grade cervical squamous intraepithelial lesion after 2 years of treatment.</measure>
    <time_frame>24 months</time_frame>
    <description>To evaluate the recurrence after 2 years of the end of the immunomodulatory topical treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of reoperation rate after immunomodulatory treatment associated with standard treatment with LEEP compared to LEEP alone.</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluation of reoperation rate in post-treatment follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance HPV</measure>
    <time_frame>30 months</time_frame>
    <description>To evaluate the persistence or not of the HPV virus and which specific type to relate to the efficacy of the immunomodulatory treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Uterine Cervical Neoplasm</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Will be offered the standard treatment, which is the conization of the uterine cervix with loop electrosurgical excision procedure (LEEP).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imiquimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will receive topical uterine cervix (Imiquimod) treatment for a period of 12 weeks with weekly applications (1x / week). 30-60 days afterwards they will be submitted to standard treatment with conization of the uterine cervix with loop electrosurgical excision procedure (LEEP).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Exertion of the cervix transformation zone</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Imiquimod</arm_group_label>
    <other_name>loop electrosurgical excision procedure</other_name>
    <other_name>Conization of the cervix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod</intervention_name>
    <description>Application by the doctor of immunomodulatory cream on the uterine cervix 1 time per week for 12 weeks</description>
    <arm_group_label>Imiquimod</arm_group_label>
    <other_name>Imiquimod 5% cream</other_name>
    <other_name>Ixium 5%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women between 25 and 50 years old with a diagnosis of CIN 2/3;

          -  Satisfactory colposcopy (squamocolumnar junction fully visible or partially visible);

          -  Negative pregnancy test result for women of childbearing potential;

          -  Be doing the first treatment for high-grade cervical intraepithelial lesion;

          -  Living 200 km or less from the city of Barretos-São Paulo / Brazil.

        Exclusion Criteria:

          -  Women with suspected cervical cancer at colposcopy or biopsy;

          -  Pregnant or lactating patients;

          -  Patients with some immunodeficiency, transplanted or carrying the human
             immunodeficiency virus.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo D Reis, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Barretos Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno DO Fonseca, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barretos Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruno DO Fonseca, MD</last_name>
    <phone>+55 17996761142</phone>
    <email>bolfonseca1@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ricardo D Reis, PhD</last_name>
    <phone>+55 1733216600</phone>
    <phone_ext>7126</phone_ext>
    <email>drricardoreis@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Barretos Cancer Hospital</name>
      <address>
        <city>Barretos</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Reis, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <results_reference>
    <citation>American College of Obstetricians and Gynecologists. Practice Bulletin No. 140: management of abnormal cervical cancer screening test results and cervical cancer precursors. Obstet Gynecol. 2013 Dec;122(6):1338-67. doi: 10.1097/01.AOG.0000438960.31355.9e.</citation>
    <PMID>24264713</PMID>
  </results_reference>
  <results_reference>
    <citation>Martin-Hirsch PP, Paraskevaidis E, Bryant A, Dickinson HO, Keep SL. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev. 2010 Jun 16;(6):CD001318. doi: 10.1002/14651858.CD001318.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;12:CD001318.</citation>
    <PMID>20556751</PMID>
  </results_reference>
  <results_reference>
    <citation>Lin CT, Qiu JT, Wang CJ, Chang SD, Tang YH, Wu PJ, Jung SM, Huang CC, Chou HH, Jao MS, Lai CH. Topical imiquimod treatment for human papillomavirus infection in patients with and without cervical/vaginal intraepithelial neoplasia. Taiwan J Obstet Gynecol. 2012 Dec;51(4):533-8. doi: 10.1016/j.tjog.2012.09.006.</citation>
    <PMID>23276555</PMID>
  </results_reference>
  <results_reference>
    <citation>Pachman DR, Barton DL, Clayton AC, McGovern RM, Jefferies JA, Novotny PJ, Sloan JA, Loprinzi CL, Gostout BS. Randomized clinical trial of imiquimod: an adjunct to treating cervical dysplasia. Am J Obstet Gynecol. 2012 Jan;206(1):42.e1-7. doi: 10.1016/j.ajog.2011.06.105. Epub 2011 Jul 13.</citation>
    <PMID>21907959</PMID>
  </results_reference>
  <results_reference>
    <citation>McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, Skegg DC. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008 May;9(5):425-34. doi: 10.1016/S1470-2045(08)70103-7. Epub 2008 Apr 11.</citation>
    <PMID>18407790</PMID>
  </results_reference>
  <results_reference>
    <citation>Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P, Prendiville W, Paraskevaidis E. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ. 2008 Sep 18;337:a1284. doi: 10.1136/bmj.a1284. Review.</citation>
    <PMID>18801868</PMID>
  </results_reference>
  <results_reference>
    <citation>Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet. 2006 Feb 11;367(9509):489-98. Review.</citation>
    <PMID>16473126</PMID>
  </results_reference>
  <results_reference>
    <citation>Jin G, LanLan Z, Li C, Dan Z. Pregnancy outcome following loop electrosurgical excision procedure (LEEP) a systematic review and meta-analysis. Arch Gynecol Obstet. 2014 Jan;289(1):85-99. doi: 10.1007/s00404-013-2955-0. Epub 2013 Jul 11. Review.</citation>
    <PMID>23843155</PMID>
  </results_reference>
  <results_reference>
    <citation>Insinga RP, Dasbach EJ, Elbasha EH. Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis. 2009 Jul 29;9:119. doi: 10.1186/1471-2334-9-119. Review.</citation>
    <PMID>19640281</PMID>
  </results_reference>
  <results_reference>
    <citation>Kocken M, Helmerhorst TJ, Berkhof J, Louwers JA, Nobbenhuis MA, Bais AG, Hogewoning CJ, Zaal A, Verheijen RH, Snijders PJ, Meijer CJ. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol. 2011 May;12(5):441-50. doi: 10.1016/S1470-2045(11)70078-X.</citation>
    <PMID>21530398</PMID>
  </results_reference>
  <results_reference>
    <citation>Conner SN, Cahill AG, Tuuli MG, Stamilio DM, Odibo AO, Roehl KA, Macones GA. Interval from loop electrosurgical excision procedure to pregnancy and pregnancy outcomes. Obstet Gynecol. 2013 Dec;122(6):1154-9. doi: 10.1097/01.AOG.0000435454.31850.79.</citation>
    <PMID>24201682</PMID>
  </results_reference>
  <results_reference>
    <citation>Spracklen CN, Harland KK, Stegmann BJ, Saftlas AF. Cervical surgery for cervical intraepithelial neoplasia and prolonged time to conception of a live birth: a case-control study. BJOG. 2013 Jul;120(8):960-5. doi: 10.1111/1471-0528.12209. Epub 2013 Mar 14.</citation>
    <PMID>23489374</PMID>
  </results_reference>
  <results_reference>
    <citation>Grimm C, Polterauer S, Natter C, Rahhal J, Hefler L, Tempfer CB, Heinze G, Stary G, Reinthaller A, Speiser P. Treatment of cervical intraepithelial neoplasia with topical imiquimod: a randomized controlled trial. Obstet Gynecol. 2012 Jul;120(1):152-9. doi: 10.1097/AOG.0b013e31825bc6e8.</citation>
    <PMID>22914404</PMID>
  </results_reference>
  <results_reference>
    <citation>Mathiesen O, Buus SK, Cramers M. Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double-blinded study. Gynecol Oncol. 2007 Nov;107(2):219-22. Epub 2007 Jul 25.</citation>
    <PMID>17655918</PMID>
  </results_reference>
  <results_reference>
    <citation>van Seters M, van Beurden M, ten Kate FJ, Beckmann I, Ewing PC, Eijkemans MJ, Kagie MJ, Meijer CJ, Aaronson NK, Kleinjan A, Heijmans-Antonissen C, Zijlstra FJ, Burger MP, Helmerhorst TJ. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med. 2008 Apr 3;358(14):1465-73. doi: 10.1056/NEJMoa072685.</citation>
    <PMID>18385498</PMID>
  </results_reference>
  <results_reference>
    <citation>van Seters M, van Beurden M, de Craen AJ. Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. Gynecol Oncol. 2005 May;97(2):645-51. Review.</citation>
    <PMID>15863172</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen FP. Efficacy of imiquimod 5% cream for persistent human papillomavirus in genital intraepithelial neoplasm. Taiwan J Obstet Gynecol. 2013 Dec;52(4):475-8. doi: 10.1016/j.tjog.2013.10.004.</citation>
    <PMID>24411029</PMID>
  </results_reference>
  <results_reference>
    <citation>Diaz-Arrastia C, Arany I, Robazetti SC, Dinh TV, Gatalica Z, Tyring SK, Hannigan E. Clinical and molecular responses in high-grade intraepithelial neoplasia treated with topical imiquimod 5%. Clin Cancer Res. 2001 Oct;7(10):3031-3.</citation>
    <PMID>11595691</PMID>
  </results_reference>
  <results_reference>
    <citation>Gunderson CC, Nugent EK, Elfrink SH, Gold MA, Moore KN. A contemporary analysis of epidemiology and management of vaginal intraepithelial neoplasia. Am J Obstet Gynecol. 2013 May;208(5):410.e1-6. doi: 10.1016/j.ajog.2013.01.047. Epub 2013 Feb 1.</citation>
    <PMID>23380265</PMID>
  </results_reference>
  <results_reference>
    <citation>Haidopoulos D, Diakomanolis E, Rodolakis A, Voulgaris Z, Vlachos G, Intsaklis A. Can local application of imiquimod cream be an alternative mode of therapy for patients with high-grade intraepithelial lesions of the vagina? Int J Gynecol Cancer. 2005 Sep-Oct;15(5):898-902.</citation>
    <PMID>16174242</PMID>
  </results_reference>
  <results_reference>
    <citation>Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, McCalmont T, Nayar R, Palefsky JM, Stoler MH, Wilkinson EJ, Zaino RJ, Wilbur DC; Members of LAST Project Work Groups. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med. 2012 Oct;136(10):1266-97. Epub 2012 Jun 28. Erratum in: Arch Pathol Lab Med. 2013 Jun;137(6):738.</citation>
    <PMID>22742517</PMID>
  </results_reference>
  <results_reference>
    <citation>International Agency for Research on Cancer, World Health Organization, Globocan, Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012</citation>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2017</study_first_submitted>
  <study_first_submitted_qc>July 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2017</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high grade cervical intraepithelial neoplasia</keyword>
  <keyword>Immunomodulatory treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

